Michael Hoelscher
Michael Hoelscher
Direktor Tropenmedizin, Klinikum der LMU
Verified email at - Homepage
Cited by
Cited by
Virological assessment of hospitalized patients with COVID-2019
R Wölfel, VM Corman, W Guggemos, M Seilmaier, S Zange, MA Müller, ...
Nature 581 (7809), 465-469, 2020
Transmission of 2019-nCoV infection from an asymptomatic contact in Germany
C Rothe, M Schunk, P Sothmann, G Bretzel, G Froeschl, C Wallrauch, ...
New England journal of medicine 382 (10), 970-971, 2020
Global trends in molecular epidemiology of HIV-1 during 2000–2007
J Hemelaar, E Gouws, PD Ghys, S Osmanov
Aids 25 (5), 679-689, 2011
Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test
SD Lawn, P Mwaba, M Bates, A Piatek, H Alexander, BJ Marais, ...
The Lancet infectious diseases 13 (4), 349-361, 2013
Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial
G Theron, L Zijenah, D Chanda, P Clowes, A Rachow, M Lesosky, W Bara, ...
The Lancet 383 (9915), 424-435, 2014
Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000
S Osmanov, C Pattou, N Walker, B Schwardländer, J Esparza
JAIDS Journal of Acquired Immune Deficiency Syndromes 29 (2), 184-190, 2002
Operational feasibility of using loop-mediated isothermal amplification for diagnosis of pulmonary tuberculosis in microscopy centers of developing countries
CC Boehme, P Nabeta, G Henostroza, R Raqib, Z Rahim, M Gerhardt, ...
Journal of clinical microbiology 45 (6), 1936-1940, 2007
New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects
AI Zumla, SH Gillespie, M Hoelscher, PPJ Philips, ST Cole, I Abubakar, ...
The Lancet infectious diseases 14 (4), 327-340, 2014
Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting
G Theron, J Peter, R van Zyl-Smit, H Mishra, E Streicher, S Murray, ...
American journal of respiratory and critical care medicine 184 (1), 132-140, 2011
Virological assessment of hospitalized cases of coronavirus disease 2019
KZ Ehmann, C Drosten, C Wendtner, MD Zange, P Vollmar, ...
Nature 581, 465-469, 2020
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
MJ Boeree, N Heinrich, R Aarnoutse, AH Diacon, R Dawson, S Rehal, ...
The Lancet infectious diseases 17 (1), 39-49, 2017
Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages
D Stucki, D Brites, L Jeljeli, M Coscolla, Q Liu, A Trauner, L Fenner, ...
Nature genetics 48 (12), 1535-1543, 2016
Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts
BJ Marais, K Lönnroth, SD Lawn, GB Migliori, P Mwaba, P Glaziou, ...
The Lancet infectious diseases 13 (5), 436-448, 2013
Drug-resistant tuberculosis: time for visionary political leadership
I Abubakar, M Zignol, D Falzon, M Raviglione, L Ditiu, S Masham, I Adetifa, ...
The Lancet infectious diseases 13 (6), 529-539, 2013
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis
MJ Boeree, AH Diacon, R Dawson, K Narunsky, J Du Bois, A Venter, ...
American journal of respiratory and critical care medicine 191 (9), 1058-1065, 2015
Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis
G Riedner, M Rusizoka, J Todd, L Maboko, M Hoelscher, D Mmbando, ...
New England Journal of Medicine 353 (12), 1236-1244, 2005
Prospective study of acute HIV-1 infection in adults in East Africa and Thailand
ML Robb, LA Eller, H Kibuuka, K Rono, L Maganga, S Nitayaphan, ...
New England Journal of Medicine 374 (22), 2120-2130, 2016
Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers
RS Wallis, M Maeurer, P Mwaba, J Chakaya, R Rustomjee, GB Migliori, ...
The Lancet infectious diseases 16 (4), e34-e46, 2016
Host-directed therapies for infectious diseases: current status, recent progress, and future prospects
A Zumla, M Rao, RS Wallis, SHE Kaufmann, R Rustomjee, P Mwaba, ...
The Lancet Infectious Diseases 16 (4), e47-e63, 2016
Preferential infection and depletion of Mycobacterium tuberculosis–specific CD4 T cells after HIV-1 infection
C Geldmacher, N Ngwenyama, A Schuetz, C Petrovas, K Reither, ...
Journal of Experimental Medicine 207 (13), 2869-2881, 2010
The system can't perform the operation now. Try again later.
Articles 1–20